234 related articles for article (PubMed ID: 17565496)
21. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V
Int J Mol Med; 2007 Sep; 20(3):397-404. PubMed ID: 17671747
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.
Tolmachev V; Altai M; Sandström M; Perols A; Karlström AE; Boschetti F; Orlova A
Bioconjug Chem; 2011 May; 22(5):894-902. PubMed ID: 21443270
[TBL] [Abstract][Full Text] [Related]
23. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
Tran T; Engfeldt T; Orlova A; Widström C; Bruskin A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(2):549-58. PubMed ID: 17330952
[TBL] [Abstract][Full Text] [Related]
24. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
[TBL] [Abstract][Full Text] [Related]
25. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
26. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
27. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
28. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
30. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
[TBL] [Abstract][Full Text] [Related]
31. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide.
Maresca KP; Marquis JC; Hillier SM; Lu G; Femia FJ; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
Bioconjug Chem; 2010 Jun; 21(6):1032-42. PubMed ID: 20402463
[TBL] [Abstract][Full Text] [Related]
32. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
[TBL] [Abstract][Full Text] [Related]
33. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
[TBL] [Abstract][Full Text] [Related]
35. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.
Tolmachev V; Wållberg H; Sandström M; Hansson M; Wennborg A; Orlova A
Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):531-9. PubMed ID: 21069318
[TBL] [Abstract][Full Text] [Related]
36. Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours.
Abiraj K; Mansi R; Tamma ML; Forrer F; Cescato R; Reubi JC; Akyel KG; Maecke HR
Chemistry; 2010 Feb; 16(7):2115-24. PubMed ID: 20066690
[TBL] [Abstract][Full Text] [Related]
37. [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.
Orlova A; Hofström C; Strand J; Varasteh Z; Sandstrom M; Andersson K; Tolmachev V; Gräslund T
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):439-49. PubMed ID: 23179942
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
Altai M; Perols A; Karlström AE; Sandström M; Boschetti F; Orlova A; Tolmachev V
Nucl Med Biol; 2012 May; 39(4):518-29. PubMed ID: 22172396
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.
Tran TA; Rosik D; Abrahmsén L; Sandström M; Sjöberg A; Wållberg H; Ahlgren S; Orlova A; Tolmachev V
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1864-73. PubMed ID: 19504093
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]